文献速递自身炎症与 IgG4 相关病

如何治疗VEXAS综合征:当前治疗策略有效性与安全性的系统综述

How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

该系统综述共纳入36篇文献、116例VEXAS综合征患者(113例,98.3%为男性),评估了阿扎胞苷、JAK抑制剂、托珠单抗、异基因造血干细胞移植、阿那白滞素、卡那奴单抗及糖皮质激素单药等治疗的反应与安全性。当前数据有限且异质性大,治疗应个体化;不良事件尤其是JAK抑制剂相关的静脉血栓栓塞风险需谨慎考虑。

要点

  • 异基因造血干细胞移植完全缓解6/7(85.7%),1例死亡。
  • 阿扎胞苷完全缓解9/36(25%)、部分缓解14/36(38.9%)。
  • JAK抑制剂完全缓解11/33(33%)、部分缓解9/33(27.3%),需警惕静脉血栓栓塞风险。

核心结论

  • 当前VEXAS治疗数据有限且异质性大,治疗决策应个体化,制定治疗算法需临床试验。
  • 不良事件仍是挑战,尤其JAK抑制剂治疗相关的静脉血栓栓塞风险升高应仔细考虑。

研究设计与样本

  • 按PRISMA指南开展的系统综述,检索三个数据库,对纳入文献进行叙述性综合。

主要发现

  • 共纳入36篇文献、116例患者,其中113例(98.3%)为男性。
  • 阿扎胞苷完全缓解9/36(25%)、部分缓解14/36(38.9%);JAK抑制剂完全缓解11/33(33%)、部分缓解9/33(27.3%)。
  • 托珠单抗完全缓解3/15(20%)、部分缓解6/15(40%);异基因造血干细胞移植完全缓解6/7(85.7%),1例死亡。
  • 阿那白滞素完全缓解4/5(80%)、无缓解1/5(20%);卡那奴单抗完全缓解1/2(50%)、部分缓解1/2(50%);糖皮质激素单药完全缓解1/6(16.7%)、部分缓解4/6(66.7%)。
  • 67例(67/116,57.8%)有不良事件数据:肺炎12/67(17.9%)、其他感染9/67(13.4%)、静脉血栓栓塞6/67(8.9%)、血细胞减少4/67(5.9%)、急性移植物抗宿主病4/67(5.9%)、慢性移植物抗宿主病2/67(2.9%)。

关键数值与推荐

  • 治疗反应按临床症状和实验室指标变化记录为完全缓解(CR)、部分缓解(PR)或无缓解(NR)。
  • TNF抑制剂、利妥昔单抗和甲氨蝶呤仅有个案报告。

临床怎么用

  • 作者认为当前VEXAS治疗数据有限且异质性大,治疗决策应个体化。
  • 作者认为制定治疗算法需临床试验。
  • 作者认为应仔细考虑JAK抑制剂治疗相关的静脉血栓栓塞风险升高。

局限性

  • 当前VEXAS治疗数据有限且异质性大。
  • 制定治疗算法需临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the effectiveness and safety of current treatment strategies for the vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. METHODS: A protocolized systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was performed. Three databases were searched for reports on treatment strategies for VEXAS. Data from the included publications was extracted and a narrative synthesis was performed. Treatment response was recorded as complete (CR), partial (PR) or none (NR) depending on changes in clinical symptoms and laboratory parameters. Patient characteristics, safety data and previous treatments were analysed. RESULTS: We identified 36 publications with a total of 116 patients; 113 (98.3%) were male. The identified reports included azacytidine (CR 9/36, 25%; PR 14/36, 38.9%), Janus kinase inhibitors (JAKi) (CR 11/33, 33%; PR 9/33, 27.3%), tocilizumab (CR 3/15, 20%; PR 6/15, 40%), allogeneic stem cell transplantation (CR 6/7, 85.7%; one patient died), anakinra (CR 4/5, 80%; NR 1/5, 20%), canakinumab (CR 1/2, 50%; PR 1/2, 50%) and glucocorticoid monotherapy (CR 1/6, 16.7%; PR 4/6, 66.7%). Individual reports were available for TNF inhibitors, rituximab and MTX. Data on adverse events were available for 67 patients (67/116, 57.8%) and included: pneumonia (12/67, 17.9%), other infections (9/67, 13.4%), venous thromboembolisms (6/67, 8.9%), cytopenias (4/67, 5.9%), and acute (4/67, 5.9%) and chronic graft-vs-host-disease (2/67, 2.9%). CONCLUSION: Current data on VEXAS treatment are limited and inhomogeneous. Treatment decisions should be individualized. For the devolvement of treatment algorithms clinical trials are needed. Adverse events remain a challenge, especially an elevated risk for venous thromboembolism associated to JAKi treatment should be carefully considered.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Boyadzhieva Z, Ruffer N, Kötter I, et al. How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies. Rheumatology (Oxford). 2023. PMID: 37233149. doi:10.1093/rheumatology/kead240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。